Lynx1 Capital Management LP bought $2.1M of CGEM
owner at Cullinan Therapeutics, Inc.. 248,749 shares at an average of $8.46, traded Oct 14, 2025, filed Oct 21, 2025.
Score components
- +12Role10% owner
- +25Trade size$2.1M at market
- 0Relative to holdingsHoldings up 2.9%
- +8Price context56% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (1 with prices)
- -5Outside holderA 10% owner who is not an officer or director
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +2.8%, 3m +28.2%, 6m +67.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000902664-25-004499, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 14, 2025 | POpen-market purchase Common stock, $0.0001 par value per share ("Common Stock")indirect: See footnote | +15,032 | $7.59 | $114k | 8,564,116 | Oct 21, 2025 |
| Oct 15, 2025 | POpen-market purchase Common Stockindirect: See footnote | +51,500 | $7.94 | $409k | 8,615,616 | Oct 21, 2025 |
| Oct 16, 2025 | POpen-market purchase Common Stockindirect: See footnote | +150,000 | $8.86 | $1.3M | 8,765,616 | Oct 21, 2025 |
| Oct 17, 2025 | POpen-market purchase Common Stockindirect: See footnote | +32,217 | $7.84 | $253k | 8,797,833 | Oct 21, 2025 |
Related signals
Other insiders at Cullinan Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 0Weak | Cullinan Therapeutics, Inc. | Jennifer Michaelson Chief Scientific Officer | $173k 8,000 shares | -5% | |
| 5Weak | Cullinan Therapeutics, Inc. | Jennifer Michaelson Chief Scientific Officer | $608k 30,000 shares | -16% | |
| 0Weak | Cullinan Therapeutics, Inc. | Jennifer Michaelson Chief Scientific Officer | $143k 8,000 shares | -5% | |
| 0Weak | Cullinan Therapeutics, Inc. | Jennifer Michaelson Chief Scientific Officer | $117k 8,000 shares | -5% | |
| 6Weak | Cullinan Therapeutics, Inc. | Jennifer Michaelson Chief Scientific Officer | $125k 8,000 shares | -4% | |
| 15Weak | Cullinan Therapeutics, Inc. | Jennifer Michaelson Chief Scientific Officer | $25k 1,780 shares | -1% | |
| 52Moderate | Cullinan Therapeutics, Inc. | Nadim Ahmed President and CEO | $196k 13,515 shares | -3% | |
| 37Weak | Cullinan Therapeutics, Inc. | Jacquelyn L Sumer Chief Legal Officer | $52k 3,601 shares | -3% | |
| 38Weak | Cullinan Therapeutics, Inc. | Jeffrey Alan Jones Chief Medical Officer | $66k 4,582 shares | -3% | |
| 18Weak | Cullinan Therapeutics, Inc. | Jennifer Michaelson Chief Scientific Officer | $77k 5,353 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.